Bayer to bring five mid-stage drugs into Phase III by 2015

FRANKFURT Tue Oct 8, 2013 2:50am EDT

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

Related Topics

Photo

Ebola epidemic

Quarantines and isolation units imposed to stop the spread of the worst Ebola outbreak in history.  Slideshow 

FRANKFURT (Reuters) - German drugmaker Bayer said it aims to bring its five most advanced mid-stage drug development projects into the third and last phase of testing on humans by 2015.

The five experimental drugs in the areas of oncology, cardiology and women's health are currently in Phase I and II of testing, Bayer said in a statement on Tuesday.

Bayer executives will make presentations to analysts later on Tuesday.

(Reporting by Ludwig Burger; Editing by Maria Sheahan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.